Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone.

Abstract

OBJECTIVES:

Various genetic polymorphisms have been reported to be associated with antipsychotic-induced weight gain. In this study, we aimed to determine whether risk polymorphisms in 12 candidate genes are associated with reduction in body mass index (BMI) of patients following switching of antipsychotics to aripiprazole or ziprasidone.

METHODS:

We recruited 115 schizophrenia patients with metabolic abnormalities and who have been on at least 1 year treatment with other antipsychotics; they were then switched to either aripiprazole or ziprasidone. They were genotyped, and their BMI monitored for 6 months.

RESULTS:

Significant associations with reduction in BMI at 6 months following switching were found in two of these genes: with rs1800544 of the ADRA2A gene (CC + CG [-0.32 ± 1.41 kg/m²] vs GG [-1.04 ± 1.63 kg/m²], p = 0.013) and with rs1801131 of the MTHFR gene (AA [-0.36 ± 1.53] vs AC + CC [-1.07 ± 1.53], p = 0.015).

CONCLUSION:

The study data indicated that carriage of the ADRA2A rs1800544 GG genotype and the MTHFR rs1801131 C allele are associated with BMI reduction in this population following switching of antipsychotics to aripiprazole and ziprasidone.

• Authors: Siti Norsyuhada Roffeei, Gavin P Reynolds, Nor Zuraida Zainal, Mas Ayu Said, Ahmad Hatim, Syarinaz Ahmad Aida, Zahurin Mohamed
• Journal: Human psychopharmacology (Hum Psychopharmacol) Vol. 29 Issue 1 Pg. 38-45 (Jan 2014) ISSN: 1099-1077 [Electronic] England
• PMID: 24424705 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2013 John Wiley & Sons, Ltd.

Chemical References

• ADRA2A protein, human
• Antipsychotic Agents
• Piperazines
• Quinolones
• Receptors, Adrenergic, alpha-2
• Thiazoles
• ziprasidone
• Aripiprazole
• MTHFR protein, human
• Methylenetetrahydrofolate Reductase (NADPH2)

Topics

• Adult
• Alleles
• Antipsychotic Agents (adverse effects, therapeutic use)
• Aripiprazole
• Body Mass Index
• Female
• Follow-Up Studies
• Genotype
• Humans
• Male
• Methylenetetrahydrofolate Reductase (NADPH2) (genetics)
• Middle Aged
• Piperazines (adverse effects, therapeutic use)
• Polymorphism, Genetic
• Quinolones (adverse effects, therapeutic use)
• Receptors, Adrenergic, alpha-2 (genetics)
• Schizophrenia (drug therapy)
• Thiazoles (adverse effects, therapeutic use)
• Weight Gain (drug effects)
• Weight Loss (genetics)